Clinical Trial Update: Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial results for LIK066 pharmacodynamics in overweight and obese women with polycystic ovary syndrome have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Ovary Syndrome

Drugs mentioned

• LIK066 (LIK066)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polycystic Ovary Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2019-05-09